Hematology Experts Highlight Emerging Trends, Research From EHA 2026 Congress

Why It Matters

The advances reshape treatment algorithms, offering more effective, targeted options while challenging existing standards and reimbursement models across hematology.

Key Takeaways

• CAR‑T and bispecific antibodies expanding in lymphoma and CLL
• Venetoclax optimization and triplet combos emerging for AML
• Talquetamab shows superiority over daratumumab triplets in myeloma
• New myeloma options complicate treatment sequencing across early lines
• Sickle cell trials need broader endpoints to include 50‑60% patients

Pulse Analysis

The 31st European Hematology Association (EHA) Congress in Stockholm gathered leading clinicians and researchers to showcase the rapid evolution of immunotherapy in blood cancers. Speakers highlighted in‑vivo CAR‑T advances, bispecific antibodies for lymphoma, and novel Bruton tyrosine kinase degraders that are reshaping chronic lymphocytic leukemia regimens. In acute myeloid leukemia, data focused on fine‑tuning venetoclax exposure and testing triplet combinations to improve remission durability. The consensus was clear: the therapeutic toolbox is expanding faster than ever, demanding new clinical strategies.

Multiple myeloma emerged as a showcase of that shift. The MonumenTAL‑3 trial demonstrated that talquetamab‑based, BCMA‑sparing regimens outperform the long‑standing daratumumab‑pomalidomide‑dexamethasone triplet, even though talquetamab is currently approved only after four prior lines. Investigators anticipate moving the drug into earlier lines, where it will sit alongside BCMA‑directed CAR‑T, BCMA bispecifics, GPRC5D bispecifics, and the antibody‑drug conjugate belantamab mafodotin. This crowded landscape forces physicians to navigate a more complex sequencing algorithm, but it also promises higher response rates and deeper remissions for patients.

Beyond myeloma, the congress underscored progress in chronic lymphocytic leukemia, acute myeloid leukemia, and sickle cell disease. Combination strategies that pair venetoclax with novel agents aim to shorten therapy duration while maintaining efficacy. Meanwhile, Dr. Kanter called attention to the narrow eligibility criteria of sickle‑cell trials, urging broader endpoints that would capture 50‑60 % of the patient population and accelerate therapeutic innovation. As immunotherapy becomes the new standard across hematologic malignancies, payers and providers must adapt reimbursement models and real‑world evidence frameworks to sustain rapid adoption while ensuring patient safety.